SlideShare a Scribd company logo
Response to a warning letter
Submitted by ,
JAYA PRAKASH V,
M.pharmacy 1st year,
Regulatory affairs.
About the letter…
 This warning letter was given to the XYZ labs private
limited unit 5 which was located at ABCD region.
 It was a formulation unit.
 Which was issued by the FDA on August 15 2017
 The observations and responses are as follows:
 1. Observation :
Your firm failed to clean, maintain, and, as appropriate
for the nature of the drug, sanitize and/or sterilize
equipment and utensils at appropriate intervals to
prevent malfunctions or contamination that would alter
the safety, identity, strength, quality, or purity of the
drug product beyond the official or other established
requirements.
 Observation 1(A):
• (b)(4) PDE-2095 had white residue on and around a
white interior gasket.
• Our investigator documented a gap in the gasket that
could allow processed materials to accumulate. The ends
of the gasket were also in poor condition.
 Response:
 The white residue on the white interior gasket of (b)(4)
was not the residue. Where they are the water drops after
cleaning , as we placed it for drying .
 Where the gap in the gasket and poor condition of the
gasket of one particular (b)(4) was already kept under
maintenance before your inspections starts .
 where the tag or label not kept by our personnel ,which
your investigator identifies as a defect.
 Corrective action:
 By this our firm implemented the training program for
the personnel on proper labeling and tagging to the
equipment which are kept for under maintenance and
incident. And also planned a training program for
personnel who are involved in the cleaning activity.
 Observation 1(B):
Our investigators observed multiple (b)(4), which you
identified as clean, containing colored residue and/or in
poor condition.
 Response:
 As the colored residue on the (b)(4) found in your
observation was sampled and analyzed to identify and
quantify any chemical and microbiological
contaminants.
 And the results met microbial contaminants.
 As our team investigated the root cause for the colored
residue on the cleaned (b)(4) .
 It was finally found that the residue is due to improper
cleaning of that particular multiple (b)(4) by our
personnel ,which was only found in the block-5 and
block-6 of manufacturing area.
 Corrective action:
 By this observation our firm implementing proper
training plan to the personnel responsible for cleaning,
verifying equipment cleanliness, and maintaining
equipment.
 which is capable of performing their assigned duties.
Include cleaning validation was done.
 And also we are implementing self inspection program
to evaluate and minimize the defects.
 2.Observation:
 Your firm failed to establish adequate written
responsibilities and procedures applicable to the quality
control unit and to follow such written procedures.
 Your firm’s procedures, QM001-04 Quality System
Manual and CQA012-01 Product Recall, direct your
firm to recall products , but your quality control unit
failed to follow your written procedures regarding the
recall of failing product.
 On July 8, 2016, you received a complaint that one
tablet in a bottle of 5 mg finasteride tablets, lot
FIN16002, was approximately double the thickness of
the others. You confirmed the defect after receiving the
complaint sample on July 27, 2016, but did not initiate a
product recall as directed by your own procedures until
investigators pointed out.
 Response:
 As our firm has an efficient quality system manual and
product recall procedure.
 But distribution record for that particular product was
destroyed along with the expiry products distribution
records.
 Which this happens because of the misplacing of the
distribution records of that product by our personnel
 Corrective action:
 Where the personnel involved in this activity have been
removed from our firm.
 We implemented the training program for the personnel
responsible for storing, archiving ,destroying of the
distribution records.
 And revising the sops , how to handle the distribution
records.
 3.Observation
 Your firm failed to thoroughly investigate failure of a
batch or any of its components to meet any of its
specifications, whether or not the batch has already been
distributed.
 For example, you have acted as the contract
manufacturer of (b)(4) mg (b)(4) tablets for multiple
customers. In February 2017, you received a customer
complaint that lot (b)(4) failed dissolution testing.
 Response :
 We thoroughly investigate the batch failure of (b)(4) by
root cause analysis on your observation.
 The cause for the batch failure was due to the campaign
manufacturing.
 Corrective action:
 We are implemented the duration time for manufacturing
and proper cleaning procedures.
 And proper training program for the personnel in
manufacturing and cleaning personnel.
THANK U

More Related Content

What's hot

Process deviation
Process deviationProcess deviation
Process deviation
GovindarajulaJP
 
Good Manufacturing Practices(GMP)
Good Manufacturing Practices(GMP)Good Manufacturing Practices(GMP)
Good Manufacturing Practices(GMP)
Virendra Singh
 
Good Laboratory Practices for Pharmaceutical Quality Control Laboratories
Good Laboratory Practices for Pharmaceutical Quality Control LaboratoriesGood Laboratory Practices for Pharmaceutical Quality Control Laboratories
Good Laboratory Practices for Pharmaceutical Quality Control Laboratories
Sathish Vemula
 
Auditing in pharmacutical industries
Auditing in pharmacutical industriesAuditing in pharmacutical industries
Auditing in pharmacutical industries
Priyanka Kandhare
 
Finished pdt. release 112070804015
Finished pdt. release  112070804015Finished pdt. release  112070804015
Finished pdt. release 112070804015
Patel Parth
 
Audit and Regulatory compliance
Audit and Regulatory complianceAudit and Regulatory compliance
Audit and Regulatory compliance
Soham Bhalekar
 
Standard operating procedure in pharmaceutical industries,SOP,MFR,Master Form...
Standard operating procedure in pharmaceutical industries,SOP,MFR,Master Form...Standard operating procedure in pharmaceutical industries,SOP,MFR,Master Form...
Standard operating procedure in pharmaceutical industries,SOP,MFR,Master Form...
SimranKukreja4
 
Return and recall
Return and recallReturn and recall
Return and recall
Hammad Md Athar
 
presentation of sampling , testing ,release and rejection of Raw materials
 presentation of sampling , testing ,release and rejection of Raw materials presentation of sampling , testing ,release and rejection of Raw materials
presentation of sampling , testing ,release and rejection of Raw materials
shaik malangsha
 
CAPA
CAPACAPA
Market complaints
Market complaintsMarket complaints
Market complaints
Ram Mohan S R
 
Recall of ph product
Recall of ph productRecall of ph product
Recall of ph product
Ahmed Suhail
 
Good Documentation Practices
Good Documentation PracticesGood Documentation Practices
Good Documentation Practices
kiranreddy munnangi
 
Product Recall.pdf
Product Recall.pdfProduct Recall.pdf
Product Recall.pdf
Md. Zakaria Faruki
 
Validation of dry heat sterilization
Validation of dry heat sterilizationValidation of dry heat sterilization
Validation of dry heat sterilization
Deepak Shanbhag
 
Deviation and root cause analysis in Pharma
Deviation and root cause analysis in PharmaDeviation and root cause analysis in Pharma
Deviation and root cause analysis in Pharma
Subhash Sanghani
 
Good Documentation Practice (GDP)
Good Documentation Practice (GDP)Good Documentation Practice (GDP)
Good Documentation Practice (GDP)
Hossen M. Faruk
 
Good Documentation Practices -Do's and Don'ts- (GCP)
Good Documentation Practices -Do's and Don'ts- (GCP)Good Documentation Practices -Do's and Don'ts- (GCP)
Good Documentation Practices -Do's and Don'ts- (GCP)
Piyush Wagh
 
CAPA Training Presentation
CAPA Training PresentationCAPA Training Presentation
CAPA Training Presentation
Nancy Watts
 
CHAPTER-1 Information Gathering and Administration.pdf
CHAPTER-1 Information Gathering and Administration.pdfCHAPTER-1 Information Gathering and Administration.pdf
CHAPTER-1 Information Gathering and Administration.pdf
Dr. Dinesh Mehta
 

What's hot (20)

Process deviation
Process deviationProcess deviation
Process deviation
 
Good Manufacturing Practices(GMP)
Good Manufacturing Practices(GMP)Good Manufacturing Practices(GMP)
Good Manufacturing Practices(GMP)
 
Good Laboratory Practices for Pharmaceutical Quality Control Laboratories
Good Laboratory Practices for Pharmaceutical Quality Control LaboratoriesGood Laboratory Practices for Pharmaceutical Quality Control Laboratories
Good Laboratory Practices for Pharmaceutical Quality Control Laboratories
 
Auditing in pharmacutical industries
Auditing in pharmacutical industriesAuditing in pharmacutical industries
Auditing in pharmacutical industries
 
Finished pdt. release 112070804015
Finished pdt. release  112070804015Finished pdt. release  112070804015
Finished pdt. release 112070804015
 
Audit and Regulatory compliance
Audit and Regulatory complianceAudit and Regulatory compliance
Audit and Regulatory compliance
 
Standard operating procedure in pharmaceutical industries,SOP,MFR,Master Form...
Standard operating procedure in pharmaceutical industries,SOP,MFR,Master Form...Standard operating procedure in pharmaceutical industries,SOP,MFR,Master Form...
Standard operating procedure in pharmaceutical industries,SOP,MFR,Master Form...
 
Return and recall
Return and recallReturn and recall
Return and recall
 
presentation of sampling , testing ,release and rejection of Raw materials
 presentation of sampling , testing ,release and rejection of Raw materials presentation of sampling , testing ,release and rejection of Raw materials
presentation of sampling , testing ,release and rejection of Raw materials
 
CAPA
CAPACAPA
CAPA
 
Market complaints
Market complaintsMarket complaints
Market complaints
 
Recall of ph product
Recall of ph productRecall of ph product
Recall of ph product
 
Good Documentation Practices
Good Documentation PracticesGood Documentation Practices
Good Documentation Practices
 
Product Recall.pdf
Product Recall.pdfProduct Recall.pdf
Product Recall.pdf
 
Validation of dry heat sterilization
Validation of dry heat sterilizationValidation of dry heat sterilization
Validation of dry heat sterilization
 
Deviation and root cause analysis in Pharma
Deviation and root cause analysis in PharmaDeviation and root cause analysis in Pharma
Deviation and root cause analysis in Pharma
 
Good Documentation Practice (GDP)
Good Documentation Practice (GDP)Good Documentation Practice (GDP)
Good Documentation Practice (GDP)
 
Good Documentation Practices -Do's and Don'ts- (GCP)
Good Documentation Practices -Do's and Don'ts- (GCP)Good Documentation Practices -Do's and Don'ts- (GCP)
Good Documentation Practices -Do's and Don'ts- (GCP)
 
CAPA Training Presentation
CAPA Training PresentationCAPA Training Presentation
CAPA Training Presentation
 
CHAPTER-1 Information Gathering and Administration.pdf
CHAPTER-1 Information Gathering and Administration.pdfCHAPTER-1 Information Gathering and Administration.pdf
CHAPTER-1 Information Gathering and Administration.pdf
 

Similar to Response to a warning letter

July 2015
July 2015July 2015
4. Design, Trust & Control of Sterile Manufacturing (Observations)
4. Design, Trust & Control of Sterile Manufacturing (Observations)4. Design, Trust & Control of Sterile Manufacturing (Observations)
4. Design, Trust & Control of Sterile Manufacturing (Observations)
Obaid Ali / Roohi B. Obaid
 
complaint and its handling
complaint and its handlingcomplaint and its handling
complaint and its handling
SaniyaShaikh579803
 
A case study on audit of pharmaceutical company
A case study on audit of pharmaceutical companyA case study on audit of pharmaceutical company
A case study on audit of pharmaceutical company
YashadaKumbhar
 
Albion presentation1.pptx
Albion presentation1.pptxAlbion presentation1.pptx
Albion presentation1.pptx
ArifulIslamRajib
 
GOOD LABORATORY PRACTICES
GOOD LABORATORY PRACTICES GOOD LABORATORY PRACTICES
GOOD LABORATORY PRACTICES
Asst Prof SSNAIK ENTO PJTSAU
 
GMP compliances of Audit
GMP compliances of AuditGMP compliances of Audit
GMP compliances of Audit
Megha bhise
 
HACCP_audit_checklist from food plannfix
HACCP_audit_checklist from food plannfixHACCP_audit_checklist from food plannfix
HACCP_audit_checklist from food plannfix
SukaesihSuma
 
Mock Response to a FDA Warning Letter
Mock Response to a FDA Warning LetterMock Response to a FDA Warning Letter
Mock Response to a FDA Warning Letter
muna_ali
 
Vendor Audit
Vendor Audit Vendor Audit
Vendor Audit
PRAVADA
 
Quality improvement and cost reduction (project by project appoach)
Quality improvement and cost reduction (project by project appoach)Quality improvement and cost reduction (project by project appoach)
Quality improvement and cost reduction (project by project appoach)
JinalPrajapati13
 
Responding Effectively to FDA 483 Observations & Warning Letters
Responding Effectively to FDA 483 Observations & Warning LettersResponding Effectively to FDA 483 Observations & Warning Letters
Responding Effectively to FDA 483 Observations & Warning Letters
Maetrics
 
Good laboratory practices (GLP) himanshu
Good laboratory practices (GLP) himanshuGood laboratory practices (GLP) himanshu
Good laboratory practices (GLP) himanshu
himanshu kamboj
 
Checklist2
Checklist2Checklist2
Checklist2
Fulya Karabasoglu
 
Glp ppt
Glp pptGlp ppt
PMG Newsletter (Volume 03. Issue 07) (12).pdf
PMG Newsletter (Volume 03. Issue 07) (12).pdfPMG Newsletter (Volume 03. Issue 07) (12).pdf
PMG Newsletter (Volume 03. Issue 07) (12).pdf
PMG Engineering Private Limited
 
Quality Assurance Unit IV Complaints.
Quality Assurance Unit IV Complaints.Quality Assurance Unit IV Complaints.
Quality Assurance Unit IV Complaints.
Rohini Kakade
 
GOOD LABORATORY PRACTICES
GOOD LABORATORY PRACTICES GOOD LABORATORY PRACTICES
GOOD LABORATORY PRACTICES
anubhavdubey18
 
PPT ON INDUSTRIAL VISIT.pptx
PPT ON INDUSTRIAL VISIT.pptxPPT ON INDUSTRIAL VISIT.pptx
PPT ON INDUSTRIAL VISIT.pptx
ajay964632
 
Good laboratory practices awervness course ay
Good laboratory practices awervness course ayGood laboratory practices awervness course ay
Good laboratory practices awervness course ay
Adel Younis
 

Similar to Response to a warning letter (20)

July 2015
July 2015July 2015
July 2015
 
4. Design, Trust & Control of Sterile Manufacturing (Observations)
4. Design, Trust & Control of Sterile Manufacturing (Observations)4. Design, Trust & Control of Sterile Manufacturing (Observations)
4. Design, Trust & Control of Sterile Manufacturing (Observations)
 
complaint and its handling
complaint and its handlingcomplaint and its handling
complaint and its handling
 
A case study on audit of pharmaceutical company
A case study on audit of pharmaceutical companyA case study on audit of pharmaceutical company
A case study on audit of pharmaceutical company
 
Albion presentation1.pptx
Albion presentation1.pptxAlbion presentation1.pptx
Albion presentation1.pptx
 
GOOD LABORATORY PRACTICES
GOOD LABORATORY PRACTICES GOOD LABORATORY PRACTICES
GOOD LABORATORY PRACTICES
 
GMP compliances of Audit
GMP compliances of AuditGMP compliances of Audit
GMP compliances of Audit
 
HACCP_audit_checklist from food plannfix
HACCP_audit_checklist from food plannfixHACCP_audit_checklist from food plannfix
HACCP_audit_checklist from food plannfix
 
Mock Response to a FDA Warning Letter
Mock Response to a FDA Warning LetterMock Response to a FDA Warning Letter
Mock Response to a FDA Warning Letter
 
Vendor Audit
Vendor Audit Vendor Audit
Vendor Audit
 
Quality improvement and cost reduction (project by project appoach)
Quality improvement and cost reduction (project by project appoach)Quality improvement and cost reduction (project by project appoach)
Quality improvement and cost reduction (project by project appoach)
 
Responding Effectively to FDA 483 Observations & Warning Letters
Responding Effectively to FDA 483 Observations & Warning LettersResponding Effectively to FDA 483 Observations & Warning Letters
Responding Effectively to FDA 483 Observations & Warning Letters
 
Good laboratory practices (GLP) himanshu
Good laboratory practices (GLP) himanshuGood laboratory practices (GLP) himanshu
Good laboratory practices (GLP) himanshu
 
Checklist2
Checklist2Checklist2
Checklist2
 
Glp ppt
Glp pptGlp ppt
Glp ppt
 
PMG Newsletter (Volume 03. Issue 07) (12).pdf
PMG Newsletter (Volume 03. Issue 07) (12).pdfPMG Newsletter (Volume 03. Issue 07) (12).pdf
PMG Newsletter (Volume 03. Issue 07) (12).pdf
 
Quality Assurance Unit IV Complaints.
Quality Assurance Unit IV Complaints.Quality Assurance Unit IV Complaints.
Quality Assurance Unit IV Complaints.
 
GOOD LABORATORY PRACTICES
GOOD LABORATORY PRACTICES GOOD LABORATORY PRACTICES
GOOD LABORATORY PRACTICES
 
PPT ON INDUSTRIAL VISIT.pptx
PPT ON INDUSTRIAL VISIT.pptxPPT ON INDUSTRIAL VISIT.pptx
PPT ON INDUSTRIAL VISIT.pptx
 
Good laboratory practices awervness course ay
Good laboratory practices awervness course ayGood laboratory practices awervness course ay
Good laboratory practices awervness course ay
 

More from JAYA PRAKASH VELUCHURI

Tangential Flow Filtration - PPT.pptx
Tangential Flow Filtration - PPT.pptxTangential Flow Filtration - PPT.pptx
Tangential Flow Filtration - PPT.pptx
JAYA PRAKASH VELUCHURI
 
Basics of Biologics| Biosimilars| USFDA| In View of Regulatory Point.pptx
Basics of Biologics| Biosimilars| USFDA| In View of Regulatory Point.pptxBasics of Biologics| Biosimilars| USFDA| In View of Regulatory Point.pptx
Basics of Biologics| Biosimilars| USFDA| In View of Regulatory Point.pptx
JAYA PRAKASH VELUCHURI
 
HUMAN CHALLENGE STUDIES TO ACCELERATE CORONA VIRUS VACCINE LICENSURE
HUMAN CHALLENGE STUDIES TO ACCELERATE CORONA VIRUS VACCINE LICENSUREHUMAN CHALLENGE STUDIES TO ACCELERATE CORONA VIRUS VACCINE LICENSURE
HUMAN CHALLENGE STUDIES TO ACCELERATE CORONA VIRUS VACCINE LICENSURE
JAYA PRAKASH VELUCHURI
 
FIXED DOSE COMBINATIONS BANNED IN INDIA
FIXED DOSE COMBINATIONS BANNED IN INDIAFIXED DOSE COMBINATIONS BANNED IN INDIA
FIXED DOSE COMBINATIONS BANNED IN INDIA
JAYA PRAKASH VELUCHURI
 
AN OVERVIEW ON FIXED DOSE COMBINATIONS AND ITS REGULATIONS IN INDIA
AN OVERVIEW ON FIXED DOSE COMBINATIONS AND ITS REGULATIONS IN INDIA AN OVERVIEW ON FIXED DOSE COMBINATIONS AND ITS REGULATIONS IN INDIA
AN OVERVIEW ON FIXED DOSE COMBINATIONS AND ITS REGULATIONS IN INDIA
JAYA PRAKASH VELUCHURI
 
HOMEOPATHY IN INDIA AND US OVERVIEW
HOMEOPATHY IN INDIA AND US OVERVIEWHOMEOPATHY IN INDIA AND US OVERVIEW
HOMEOPATHY IN INDIA AND US OVERVIEW
JAYA PRAKASH VELUCHURI
 
FIXED DOSE COMBINATIONS REGULATIONS IN INDIA AND A CASE STUDY ON THE TOP SELL...
FIXED DOSE COMBINATIONS REGULATIONS IN INDIA AND A CASE STUDY ON THE TOP SELL...FIXED DOSE COMBINATIONS REGULATIONS IN INDIA AND A CASE STUDY ON THE TOP SELL...
FIXED DOSE COMBINATIONS REGULATIONS IN INDIA AND A CASE STUDY ON THE TOP SELL...
JAYA PRAKASH VELUCHURI
 
IMPACT OF REGULATIONS ON MEDICAL DEVICES IN CONTEXT OF INNOVATIONS
IMPACT OF REGULATIONS ON MEDICAL DEVICES IN CONTEXT OF INNOVATIONSIMPACT OF REGULATIONS ON MEDICAL DEVICES IN CONTEXT OF INNOVATIONS
IMPACT OF REGULATIONS ON MEDICAL DEVICES IN CONTEXT OF INNOVATIONS
JAYA PRAKASH VELUCHURI
 
CASE STUDY ON CHANGE CONTROL
CASE STUDY ON CHANGE CONTROLCASE STUDY ON CHANGE CONTROL
CASE STUDY ON CHANGE CONTROL
JAYA PRAKASH VELUCHURI
 
Registration requirments for cis countries
Registration requirments for cis countriesRegistration requirments for cis countries
Registration requirments for cis countries
JAYA PRAKASH VELUCHURI
 
Documentation of raw material analysis for croscarmellose sodium
Documentation of raw material analysis for croscarmellose sodiumDocumentation of raw material analysis for croscarmellose sodium
Documentation of raw material analysis for croscarmellose sodium
JAYA PRAKASH VELUCHURI
 
Market authorisation checklist for brics countries
Market authorisation checklist for brics countriesMarket authorisation checklist for brics countries
Market authorisation checklist for brics countries
JAYA PRAKASH VELUCHURI
 
Ge health care and mri
Ge health care and mriGe health care and mri
Ge health care and mri
JAYA PRAKASH VELUCHURI
 
Regulatory guidelines for the development of biologics in
Regulatory guidelines for the development of biologics inRegulatory guidelines for the development of biologics in
Regulatory guidelines for the development of biologics in
JAYA PRAKASH VELUCHURI
 
ICH AND ICH GUIDELINES
ICH AND ICH GUIDELINESICH AND ICH GUIDELINES
ICH AND ICH GUIDELINES
JAYA PRAKASH VELUCHURI
 
Mutual recognition
Mutual recognitionMutual recognition
Mutual recognition
JAYA PRAKASH VELUCHURI
 
THIN LAYER CHROMATOGRAPHY
THIN LAYER CHROMATOGRAPHYTHIN LAYER CHROMATOGRAPHY
THIN LAYER CHROMATOGRAPHY
JAYA PRAKASH VELUCHURI
 
Gamp 5 overview by jaya prakash ra
Gamp 5 overview by jaya prakash raGamp 5 overview by jaya prakash ra
Gamp 5 overview by jaya prakash ra
JAYA PRAKASH VELUCHURI
 

More from JAYA PRAKASH VELUCHURI (18)

Tangential Flow Filtration - PPT.pptx
Tangential Flow Filtration - PPT.pptxTangential Flow Filtration - PPT.pptx
Tangential Flow Filtration - PPT.pptx
 
Basics of Biologics| Biosimilars| USFDA| In View of Regulatory Point.pptx
Basics of Biologics| Biosimilars| USFDA| In View of Regulatory Point.pptxBasics of Biologics| Biosimilars| USFDA| In View of Regulatory Point.pptx
Basics of Biologics| Biosimilars| USFDA| In View of Regulatory Point.pptx
 
HUMAN CHALLENGE STUDIES TO ACCELERATE CORONA VIRUS VACCINE LICENSURE
HUMAN CHALLENGE STUDIES TO ACCELERATE CORONA VIRUS VACCINE LICENSUREHUMAN CHALLENGE STUDIES TO ACCELERATE CORONA VIRUS VACCINE LICENSURE
HUMAN CHALLENGE STUDIES TO ACCELERATE CORONA VIRUS VACCINE LICENSURE
 
FIXED DOSE COMBINATIONS BANNED IN INDIA
FIXED DOSE COMBINATIONS BANNED IN INDIAFIXED DOSE COMBINATIONS BANNED IN INDIA
FIXED DOSE COMBINATIONS BANNED IN INDIA
 
AN OVERVIEW ON FIXED DOSE COMBINATIONS AND ITS REGULATIONS IN INDIA
AN OVERVIEW ON FIXED DOSE COMBINATIONS AND ITS REGULATIONS IN INDIA AN OVERVIEW ON FIXED DOSE COMBINATIONS AND ITS REGULATIONS IN INDIA
AN OVERVIEW ON FIXED DOSE COMBINATIONS AND ITS REGULATIONS IN INDIA
 
HOMEOPATHY IN INDIA AND US OVERVIEW
HOMEOPATHY IN INDIA AND US OVERVIEWHOMEOPATHY IN INDIA AND US OVERVIEW
HOMEOPATHY IN INDIA AND US OVERVIEW
 
FIXED DOSE COMBINATIONS REGULATIONS IN INDIA AND A CASE STUDY ON THE TOP SELL...
FIXED DOSE COMBINATIONS REGULATIONS IN INDIA AND A CASE STUDY ON THE TOP SELL...FIXED DOSE COMBINATIONS REGULATIONS IN INDIA AND A CASE STUDY ON THE TOP SELL...
FIXED DOSE COMBINATIONS REGULATIONS IN INDIA AND A CASE STUDY ON THE TOP SELL...
 
IMPACT OF REGULATIONS ON MEDICAL DEVICES IN CONTEXT OF INNOVATIONS
IMPACT OF REGULATIONS ON MEDICAL DEVICES IN CONTEXT OF INNOVATIONSIMPACT OF REGULATIONS ON MEDICAL DEVICES IN CONTEXT OF INNOVATIONS
IMPACT OF REGULATIONS ON MEDICAL DEVICES IN CONTEXT OF INNOVATIONS
 
CASE STUDY ON CHANGE CONTROL
CASE STUDY ON CHANGE CONTROLCASE STUDY ON CHANGE CONTROL
CASE STUDY ON CHANGE CONTROL
 
Registration requirments for cis countries
Registration requirments for cis countriesRegistration requirments for cis countries
Registration requirments for cis countries
 
Documentation of raw material analysis for croscarmellose sodium
Documentation of raw material analysis for croscarmellose sodiumDocumentation of raw material analysis for croscarmellose sodium
Documentation of raw material analysis for croscarmellose sodium
 
Market authorisation checklist for brics countries
Market authorisation checklist for brics countriesMarket authorisation checklist for brics countries
Market authorisation checklist for brics countries
 
Ge health care and mri
Ge health care and mriGe health care and mri
Ge health care and mri
 
Regulatory guidelines for the development of biologics in
Regulatory guidelines for the development of biologics inRegulatory guidelines for the development of biologics in
Regulatory guidelines for the development of biologics in
 
ICH AND ICH GUIDELINES
ICH AND ICH GUIDELINESICH AND ICH GUIDELINES
ICH AND ICH GUIDELINES
 
Mutual recognition
Mutual recognitionMutual recognition
Mutual recognition
 
THIN LAYER CHROMATOGRAPHY
THIN LAYER CHROMATOGRAPHYTHIN LAYER CHROMATOGRAPHY
THIN LAYER CHROMATOGRAPHY
 
Gamp 5 overview by jaya prakash ra
Gamp 5 overview by jaya prakash raGamp 5 overview by jaya prakash ra
Gamp 5 overview by jaya prakash ra
 

Recently uploaded

How to Make a Field Mandatory in Odoo 17
How to Make a Field Mandatory in Odoo 17How to Make a Field Mandatory in Odoo 17
How to Make a Field Mandatory in Odoo 17
Celine George
 
Présentationvvvvvvvvvvvvvvvvvvvvvvvvvvvv2.pptx
Présentationvvvvvvvvvvvvvvvvvvvvvvvvvvvv2.pptxPrésentationvvvvvvvvvvvvvvvvvvvvvvvvvvvv2.pptx
Présentationvvvvvvvvvvvvvvvvvvvvvvvvvvvv2.pptx
siemaillard
 
math operations ued in python and all used
math operations ued in python and all usedmath operations ued in python and all used
math operations ued in python and all used
ssuser13ffe4
 
RESULTS OF THE EVALUATION QUESTIONNAIRE.pptx
RESULTS OF THE EVALUATION QUESTIONNAIRE.pptxRESULTS OF THE EVALUATION QUESTIONNAIRE.pptx
RESULTS OF THE EVALUATION QUESTIONNAIRE.pptx
zuzanka
 
SWOT analysis in the project Keeping the Memory @live.pptx
SWOT analysis in the project Keeping the Memory @live.pptxSWOT analysis in the project Keeping the Memory @live.pptx
SWOT analysis in the project Keeping the Memory @live.pptx
zuzanka
 
spot a liar (Haiqa 146).pptx Technical writhing and presentation skills
spot a liar (Haiqa 146).pptx Technical writhing and presentation skillsspot a liar (Haiqa 146).pptx Technical writhing and presentation skills
spot a liar (Haiqa 146).pptx Technical writhing and presentation skills
haiqairshad
 
BÀI TẬP BỔ TRỢ TIẾNG ANH 8 CẢ NĂM - GLOBAL SUCCESS - NĂM HỌC 2023-2024 (CÓ FI...
BÀI TẬP BỔ TRỢ TIẾNG ANH 8 CẢ NĂM - GLOBAL SUCCESS - NĂM HỌC 2023-2024 (CÓ FI...BÀI TẬP BỔ TRỢ TIẾNG ANH 8 CẢ NĂM - GLOBAL SUCCESS - NĂM HỌC 2023-2024 (CÓ FI...
BÀI TẬP BỔ TRỢ TIẾNG ANH 8 CẢ NĂM - GLOBAL SUCCESS - NĂM HỌC 2023-2024 (CÓ FI...
Nguyen Thanh Tu Collection
 
BÀI TẬP BỔ TRỢ TIẾNG ANH LỚP 9 CẢ NĂM - GLOBAL SUCCESS - NĂM HỌC 2024-2025 - ...
BÀI TẬP BỔ TRỢ TIẾNG ANH LỚP 9 CẢ NĂM - GLOBAL SUCCESS - NĂM HỌC 2024-2025 - ...BÀI TẬP BỔ TRỢ TIẾNG ANH LỚP 9 CẢ NĂM - GLOBAL SUCCESS - NĂM HỌC 2024-2025 - ...
BÀI TẬP BỔ TRỢ TIẾNG ANH LỚP 9 CẢ NĂM - GLOBAL SUCCESS - NĂM HỌC 2024-2025 - ...
Nguyen Thanh Tu Collection
 
LAND USE LAND COVER AND NDVI OF MIRZAPUR DISTRICT, UP
LAND USE LAND COVER AND NDVI OF MIRZAPUR DISTRICT, UPLAND USE LAND COVER AND NDVI OF MIRZAPUR DISTRICT, UP
LAND USE LAND COVER AND NDVI OF MIRZAPUR DISTRICT, UP
RAHUL
 
BÀI TẬP DẠY THÊM TIẾNG ANH LỚP 7 CẢ NĂM FRIENDS PLUS SÁCH CHÂN TRỜI SÁNG TẠO ...
BÀI TẬP DẠY THÊM TIẾNG ANH LỚP 7 CẢ NĂM FRIENDS PLUS SÁCH CHÂN TRỜI SÁNG TẠO ...BÀI TẬP DẠY THÊM TIẾNG ANH LỚP 7 CẢ NĂM FRIENDS PLUS SÁCH CHÂN TRỜI SÁNG TẠO ...
BÀI TẬP DẠY THÊM TIẾNG ANH LỚP 7 CẢ NĂM FRIENDS PLUS SÁCH CHÂN TRỜI SÁNG TẠO ...
Nguyen Thanh Tu Collection
 
Standardized tool for Intelligence test.
Standardized tool for Intelligence test.Standardized tool for Intelligence test.
Standardized tool for Intelligence test.
deepaannamalai16
 
BBR 2024 Summer Sessions Interview Training
BBR  2024 Summer Sessions Interview TrainingBBR  2024 Summer Sessions Interview Training
BBR 2024 Summer Sessions Interview Training
Katrina Pritchard
 
Bonku-Babus-Friend by Sathyajith Ray (9)
Bonku-Babus-Friend by Sathyajith Ray  (9)Bonku-Babus-Friend by Sathyajith Ray  (9)
Bonku-Babus-Friend by Sathyajith Ray (9)
nitinpv4ai
 
What is Digital Literacy? A guest blog from Andy McLaughlin, University of Ab...
What is Digital Literacy? A guest blog from Andy McLaughlin, University of Ab...What is Digital Literacy? A guest blog from Andy McLaughlin, University of Ab...
What is Digital Literacy? A guest blog from Andy McLaughlin, University of Ab...
GeorgeMilliken2
 
C1 Rubenstein AP HuG xxxxxxxxxxxxxx.pptx
C1 Rubenstein AP HuG xxxxxxxxxxxxxx.pptxC1 Rubenstein AP HuG xxxxxxxxxxxxxx.pptx
C1 Rubenstein AP HuG xxxxxxxxxxxxxx.pptx
mulvey2
 
NEWSPAPERS - QUESTION 1 - REVISION POWERPOINT.pptx
NEWSPAPERS - QUESTION 1 - REVISION POWERPOINT.pptxNEWSPAPERS - QUESTION 1 - REVISION POWERPOINT.pptx
NEWSPAPERS - QUESTION 1 - REVISION POWERPOINT.pptx
iammrhaywood
 
Gender and Mental Health - Counselling and Family Therapy Applications and In...
Gender and Mental Health - Counselling and Family Therapy Applications and In...Gender and Mental Health - Counselling and Family Therapy Applications and In...
Gender and Mental Health - Counselling and Family Therapy Applications and In...
PsychoTech Services
 
مصحف القراءات العشر أعد أحرف الخلاف سمير بسيوني.pdf
مصحف القراءات العشر   أعد أحرف الخلاف سمير بسيوني.pdfمصحف القراءات العشر   أعد أحرف الخلاف سمير بسيوني.pdf
مصحف القراءات العشر أعد أحرف الخلاف سمير بسيوني.pdf
سمير بسيوني
 
BIOLOGY NATIONAL EXAMINATION COUNCIL (NECO) 2024 PRACTICAL MANUAL.pptx
BIOLOGY NATIONAL EXAMINATION COUNCIL (NECO) 2024 PRACTICAL MANUAL.pptxBIOLOGY NATIONAL EXAMINATION COUNCIL (NECO) 2024 PRACTICAL MANUAL.pptx
BIOLOGY NATIONAL EXAMINATION COUNCIL (NECO) 2024 PRACTICAL MANUAL.pptx
RidwanHassanYusuf
 
UGC NET Exam Paper 1- Unit 1:Teaching Aptitude
UGC NET Exam Paper 1- Unit 1:Teaching AptitudeUGC NET Exam Paper 1- Unit 1:Teaching Aptitude
UGC NET Exam Paper 1- Unit 1:Teaching Aptitude
S. Raj Kumar
 

Recently uploaded (20)

How to Make a Field Mandatory in Odoo 17
How to Make a Field Mandatory in Odoo 17How to Make a Field Mandatory in Odoo 17
How to Make a Field Mandatory in Odoo 17
 
Présentationvvvvvvvvvvvvvvvvvvvvvvvvvvvv2.pptx
Présentationvvvvvvvvvvvvvvvvvvvvvvvvvvvv2.pptxPrésentationvvvvvvvvvvvvvvvvvvvvvvvvvvvv2.pptx
Présentationvvvvvvvvvvvvvvvvvvvvvvvvvvvv2.pptx
 
math operations ued in python and all used
math operations ued in python and all usedmath operations ued in python and all used
math operations ued in python and all used
 
RESULTS OF THE EVALUATION QUESTIONNAIRE.pptx
RESULTS OF THE EVALUATION QUESTIONNAIRE.pptxRESULTS OF THE EVALUATION QUESTIONNAIRE.pptx
RESULTS OF THE EVALUATION QUESTIONNAIRE.pptx
 
SWOT analysis in the project Keeping the Memory @live.pptx
SWOT analysis in the project Keeping the Memory @live.pptxSWOT analysis in the project Keeping the Memory @live.pptx
SWOT analysis in the project Keeping the Memory @live.pptx
 
spot a liar (Haiqa 146).pptx Technical writhing and presentation skills
spot a liar (Haiqa 146).pptx Technical writhing and presentation skillsspot a liar (Haiqa 146).pptx Technical writhing and presentation skills
spot a liar (Haiqa 146).pptx Technical writhing and presentation skills
 
BÀI TẬP BỔ TRỢ TIẾNG ANH 8 CẢ NĂM - GLOBAL SUCCESS - NĂM HỌC 2023-2024 (CÓ FI...
BÀI TẬP BỔ TRỢ TIẾNG ANH 8 CẢ NĂM - GLOBAL SUCCESS - NĂM HỌC 2023-2024 (CÓ FI...BÀI TẬP BỔ TRỢ TIẾNG ANH 8 CẢ NĂM - GLOBAL SUCCESS - NĂM HỌC 2023-2024 (CÓ FI...
BÀI TẬP BỔ TRỢ TIẾNG ANH 8 CẢ NĂM - GLOBAL SUCCESS - NĂM HỌC 2023-2024 (CÓ FI...
 
BÀI TẬP BỔ TRỢ TIẾNG ANH LỚP 9 CẢ NĂM - GLOBAL SUCCESS - NĂM HỌC 2024-2025 - ...
BÀI TẬP BỔ TRỢ TIẾNG ANH LỚP 9 CẢ NĂM - GLOBAL SUCCESS - NĂM HỌC 2024-2025 - ...BÀI TẬP BỔ TRỢ TIẾNG ANH LỚP 9 CẢ NĂM - GLOBAL SUCCESS - NĂM HỌC 2024-2025 - ...
BÀI TẬP BỔ TRỢ TIẾNG ANH LỚP 9 CẢ NĂM - GLOBAL SUCCESS - NĂM HỌC 2024-2025 - ...
 
LAND USE LAND COVER AND NDVI OF MIRZAPUR DISTRICT, UP
LAND USE LAND COVER AND NDVI OF MIRZAPUR DISTRICT, UPLAND USE LAND COVER AND NDVI OF MIRZAPUR DISTRICT, UP
LAND USE LAND COVER AND NDVI OF MIRZAPUR DISTRICT, UP
 
BÀI TẬP DẠY THÊM TIẾNG ANH LỚP 7 CẢ NĂM FRIENDS PLUS SÁCH CHÂN TRỜI SÁNG TẠO ...
BÀI TẬP DẠY THÊM TIẾNG ANH LỚP 7 CẢ NĂM FRIENDS PLUS SÁCH CHÂN TRỜI SÁNG TẠO ...BÀI TẬP DẠY THÊM TIẾNG ANH LỚP 7 CẢ NĂM FRIENDS PLUS SÁCH CHÂN TRỜI SÁNG TẠO ...
BÀI TẬP DẠY THÊM TIẾNG ANH LỚP 7 CẢ NĂM FRIENDS PLUS SÁCH CHÂN TRỜI SÁNG TẠO ...
 
Standardized tool for Intelligence test.
Standardized tool for Intelligence test.Standardized tool for Intelligence test.
Standardized tool for Intelligence test.
 
BBR 2024 Summer Sessions Interview Training
BBR  2024 Summer Sessions Interview TrainingBBR  2024 Summer Sessions Interview Training
BBR 2024 Summer Sessions Interview Training
 
Bonku-Babus-Friend by Sathyajith Ray (9)
Bonku-Babus-Friend by Sathyajith Ray  (9)Bonku-Babus-Friend by Sathyajith Ray  (9)
Bonku-Babus-Friend by Sathyajith Ray (9)
 
What is Digital Literacy? A guest blog from Andy McLaughlin, University of Ab...
What is Digital Literacy? A guest blog from Andy McLaughlin, University of Ab...What is Digital Literacy? A guest blog from Andy McLaughlin, University of Ab...
What is Digital Literacy? A guest blog from Andy McLaughlin, University of Ab...
 
C1 Rubenstein AP HuG xxxxxxxxxxxxxx.pptx
C1 Rubenstein AP HuG xxxxxxxxxxxxxx.pptxC1 Rubenstein AP HuG xxxxxxxxxxxxxx.pptx
C1 Rubenstein AP HuG xxxxxxxxxxxxxx.pptx
 
NEWSPAPERS - QUESTION 1 - REVISION POWERPOINT.pptx
NEWSPAPERS - QUESTION 1 - REVISION POWERPOINT.pptxNEWSPAPERS - QUESTION 1 - REVISION POWERPOINT.pptx
NEWSPAPERS - QUESTION 1 - REVISION POWERPOINT.pptx
 
Gender and Mental Health - Counselling and Family Therapy Applications and In...
Gender and Mental Health - Counselling and Family Therapy Applications and In...Gender and Mental Health - Counselling and Family Therapy Applications and In...
Gender and Mental Health - Counselling and Family Therapy Applications and In...
 
مصحف القراءات العشر أعد أحرف الخلاف سمير بسيوني.pdf
مصحف القراءات العشر   أعد أحرف الخلاف سمير بسيوني.pdfمصحف القراءات العشر   أعد أحرف الخلاف سمير بسيوني.pdf
مصحف القراءات العشر أعد أحرف الخلاف سمير بسيوني.pdf
 
BIOLOGY NATIONAL EXAMINATION COUNCIL (NECO) 2024 PRACTICAL MANUAL.pptx
BIOLOGY NATIONAL EXAMINATION COUNCIL (NECO) 2024 PRACTICAL MANUAL.pptxBIOLOGY NATIONAL EXAMINATION COUNCIL (NECO) 2024 PRACTICAL MANUAL.pptx
BIOLOGY NATIONAL EXAMINATION COUNCIL (NECO) 2024 PRACTICAL MANUAL.pptx
 
UGC NET Exam Paper 1- Unit 1:Teaching Aptitude
UGC NET Exam Paper 1- Unit 1:Teaching AptitudeUGC NET Exam Paper 1- Unit 1:Teaching Aptitude
UGC NET Exam Paper 1- Unit 1:Teaching Aptitude
 

Response to a warning letter

  • 1. Response to a warning letter Submitted by , JAYA PRAKASH V, M.pharmacy 1st year, Regulatory affairs.
  • 2. About the letter…  This warning letter was given to the XYZ labs private limited unit 5 which was located at ABCD region.  It was a formulation unit.  Which was issued by the FDA on August 15 2017  The observations and responses are as follows:
  • 3.  1. Observation : Your firm failed to clean, maintain, and, as appropriate for the nature of the drug, sanitize and/or sterilize equipment and utensils at appropriate intervals to prevent malfunctions or contamination that would alter the safety, identity, strength, quality, or purity of the drug product beyond the official or other established requirements.
  • 4.  Observation 1(A): • (b)(4) PDE-2095 had white residue on and around a white interior gasket. • Our investigator documented a gap in the gasket that could allow processed materials to accumulate. The ends of the gasket were also in poor condition.
  • 5.  Response:  The white residue on the white interior gasket of (b)(4) was not the residue. Where they are the water drops after cleaning , as we placed it for drying .  Where the gap in the gasket and poor condition of the gasket of one particular (b)(4) was already kept under maintenance before your inspections starts .  where the tag or label not kept by our personnel ,which your investigator identifies as a defect.
  • 6.  Corrective action:  By this our firm implemented the training program for the personnel on proper labeling and tagging to the equipment which are kept for under maintenance and incident. And also planned a training program for personnel who are involved in the cleaning activity.
  • 7.  Observation 1(B): Our investigators observed multiple (b)(4), which you identified as clean, containing colored residue and/or in poor condition.
  • 8.  Response:  As the colored residue on the (b)(4) found in your observation was sampled and analyzed to identify and quantify any chemical and microbiological contaminants.  And the results met microbial contaminants.  As our team investigated the root cause for the colored residue on the cleaned (b)(4) .  It was finally found that the residue is due to improper cleaning of that particular multiple (b)(4) by our personnel ,which was only found in the block-5 and block-6 of manufacturing area.
  • 9.  Corrective action:  By this observation our firm implementing proper training plan to the personnel responsible for cleaning, verifying equipment cleanliness, and maintaining equipment.  which is capable of performing their assigned duties. Include cleaning validation was done.  And also we are implementing self inspection program to evaluate and minimize the defects.
  • 10.  2.Observation:  Your firm failed to establish adequate written responsibilities and procedures applicable to the quality control unit and to follow such written procedures.  Your firm’s procedures, QM001-04 Quality System Manual and CQA012-01 Product Recall, direct your firm to recall products , but your quality control unit failed to follow your written procedures regarding the recall of failing product.
  • 11.  On July 8, 2016, you received a complaint that one tablet in a bottle of 5 mg finasteride tablets, lot FIN16002, was approximately double the thickness of the others. You confirmed the defect after receiving the complaint sample on July 27, 2016, but did not initiate a product recall as directed by your own procedures until investigators pointed out.
  • 12.  Response:  As our firm has an efficient quality system manual and product recall procedure.  But distribution record for that particular product was destroyed along with the expiry products distribution records.  Which this happens because of the misplacing of the distribution records of that product by our personnel
  • 13.  Corrective action:  Where the personnel involved in this activity have been removed from our firm.  We implemented the training program for the personnel responsible for storing, archiving ,destroying of the distribution records.  And revising the sops , how to handle the distribution records.
  • 14.  3.Observation  Your firm failed to thoroughly investigate failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed.  For example, you have acted as the contract manufacturer of (b)(4) mg (b)(4) tablets for multiple customers. In February 2017, you received a customer complaint that lot (b)(4) failed dissolution testing.
  • 15.  Response :  We thoroughly investigate the batch failure of (b)(4) by root cause analysis on your observation.  The cause for the batch failure was due to the campaign manufacturing.  Corrective action:  We are implemented the duration time for manufacturing and proper cleaning procedures.  And proper training program for the personnel in manufacturing and cleaning personnel.